Details der Publikation - A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence

A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence : A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - EMERALD-2

Medienart:	Klinische Studie

Erscheinungsjahr:	2023
Erschienen:	2023

Enthalten in:	WHO International Clinical Trials Registry Platform - (2023) vom: 21. Juni Zur Gesamtaufnahme - year:2023

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation) MedDRA version: 20.0Level: LLTClassification code 10077746Term: Hepatocellular carcinoma stage ISystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04] Phase: Phase 3 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-05-2019, Last updated: 2023-06-29

ICTRP ID:	EUCTR2018-004105-85-AT D910DC00001

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG004717333

Internformat


LEADER	01000caa a22002652 4500
001	CTG004717333
003	DE-627
005	20230629100628.0
007	cr uuu---uuuuu
008	210507s2023 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG004717333
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2018-004105-85-AT
035			\|a (UBBS_Klinische_Studien_WHO)D910DC00001
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence \|b A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multi Center Study of Durvalumab Monotherapy or in Combination With Bevacizumab as Adjuvant Therapy in Patients With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation - EMERALD-2
264		1	\|c 2023
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 24-05-2019, Last updated: 2023-06-29
650		4	\|a Medical Condition: Histologically or cytologically confirmed Locoregional Hepatocellular Carcinoma (HCC) and successfully completed curative therapy (resection or ablation) MedDRA version: 20.0Level: LLTClassification code 10077746Term: Hepatocellular carcinoma stage ISystem Organ Class: 100000004864;Therapeutic area: Diseases [C] - Cancer [C04]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 3
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2023) vom: 21. Juni
773	1	8	\|g year:2023 \|g day:21 \|g month:06
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2018-004105-85 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
951			\|a AR
952			\|j 2023 \|b 21 \|c 06

Zugang & Verfügbarkeit

Zugehörige Publikationen/Bände